Prothena licenses PRX019 to BMS for $80M upfront; milestones up to $617.5M

PROTHENA CORP PUBLIC LTD CO

Upfront payment of $80 million from BMS; eligible for additional development and regulatory milestones up to $242.5M.
Sales milestones up to $375M upon achieving certain annual net sales thresholds.
Tiered royalties on worldwide net sales ranging from high single-digit to high teen percentages.
Prothena obligated to run Phase 1 for PRX019; BMS may elect to take over the trial.
Research term under Master Collaboration Agreement expired on May 24, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.